

Haiquan Chen

MD, Ph.D.
Professor & Chairman, Department of Thoracic Surgery
Team Leader, Thoracic Oncology MDT
Director, Lung Cancer Center
Fudan University Shanghai Cancer Center



International Academic Association:

Active Member of the American Association for Thoracic Surgery (AATS)(2011-)
Member of the Membership Committee (AATS) (2016-2017)
AATS FOCUS Faculty 2013, 2014, 2015, 2016
AATS Focus on Thoracic Surgery: CHINA 2016 Co-Chair
AATS 2016 Annual Meeting General Thoracic Skill Co-Chair

Member of the Society of Thoracic Surgeons (STS) (2004-)
Member of the Workforce on International Relationships (STS)(2011-13、 2014-16)
International Member of the Board of Directors of the Society of Thoracic Surgeons (STS) (2016-2018)
Member of the European Society of Thoracic Surgeons (ESTS) (2015-)
Council Member of Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2016-)
Fellow of the American College of Chest Physicians (FCCP)

Vice Chief Editor:

Journal of Cancer Research and Clinical Oncology

Editorial Board member:

Journal of Thoracic and Cardiovascular Surgery
Journal of Cancer Research and Clinical Oncology
Journal of Thoracic Disease
American Journal of Translational Research

Reviewer:

Journal of Clinical Oncology, NG., Carcinogenesis, Ann Surg, British Journal of Surgery, Journal of Thoracic Oncology, JTCVS, Annals of Surgical Oncology, Annals of Thoracic Surgery, Lung Cancer

In last 5 years, over 150 articles were published in peer-review academic journal like Cancer Cell、JCO、CCR、ANN SURG、Cancer、JTCVS、ANN THORAC SURG.

Peer-Reviewed Publications

(including 134 papers as the corresponding author, IF: 694.618)

1. Zhao Y, Li G, Zhang Y, Hu H, Zhang J, Sun Y, **Chen H***. Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer. **J Thorac Cardiovasc Surg.** 2017 Oct;154(4):1420-1429.e1.(IF:4.446)

2. Zhao Y, Li G, Zheng D, Jia M, Dai W, Sun Y, **Chen H***. The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma. **J Thorac Cardiovasc Surg.** 2017 Mar;153(3):702-709.e1. **(IF:4.446)**
3. Lin D, Ma L, Ye T, Pan Y, Shao L, Song Z, Jiang S, **Chen H***, Xiang J*. Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. **J Thorac Dis.** 2017 Feb;9(2):318-326. doi: 10.21037/jtd.2017.02.19. **(IF:2.365)**
4. Luo X, Zheng S, Liu Q, Wang S, Li Y, Shen L, Li G, Li W, Zhao Y, Xu H, Wang J, Liu X, Pan Y, Hu H, Sun Y, Yang H, Xu S, **Chen H***. Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. **Transl Oncol.** 2017 Aug;10(4):485-490. doi: 10.1016/j.tranon.2017.02.002. Epub 2017 May 15. **(IF:3.025)**
5. Han H, **Chen H***. Selective lymph node dissection in early-stage non-small cell lung cancer. **J Thorac Dis.** 2017 Jul;9(7):2102-2107. doi: 10.21037/jtd.2017.06.04. **(IF:2.365)**
6. Song Z, Ye T, Ma L, Xiang J*, **Chen H***. Surgical Outcomes of Isolated Malignant Pulmonary Nodules in Patients with a History of Breast Cancer. **Ann Surg Oncol.** 2017 Nov;24(12):3748-3753. doi: 10.1245/s10434-017-6067-0. Epub 2017 Aug 28. **(IF:4.041)**
7. Yuan C#, Hu H#, Kuang M#, Chen Z, Tao X, Fang S, Sun Y, Zhang Y, **Chen H***. Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma. **Oncotarget.** 2017 Oct 27;8(62):105251-105261. doi: 10.18632/oncotarget.22165. eCollection 2017 Dec 1. **(IF:5.165)**
8. Zhang Y, Zheng D, Li Y, Pan Y, Sun Y, **Chen H***. Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma. **J Thorac Dis.** 2017 Nov;9(11):4434-4440. doi: 10.21037/jtd.2017.10.43. **(IF:2.365)**
9. Yuan C#, Hu H#, Kuang M#, Chen Z, Tao X, Fang S, Sun Y*, Zhang Y*, **Chen H***. Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma. **Oncotarget.** 2017 Oct 27;8(62):105251-105261. doi: 10.18632/oncotarget.22165. eCollection 2017 Dec 1. **(IF:5.165)**

10. Zheng D, Ye T, Hu H, Zhang Y, Sun Y, Xiang J, **Chen H***. Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer. **J Thorac Cardiovasc Surg.** 2017 Nov 3. pii: S0022-5223(17)32409-1. doi: 10.1016/j.jtcvs.2017.10.075. [Epub ahead of print] **(IF:4.446)**
11. Chen T, Luo J, Gu H, Gu Y, Huang Q, Wang Y, Zheng J, Yang Y, **Chen H***. Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma. **Ann Thorac Surg.** 2018 Jan;105(1):302-308. doi: 10.1016/j.athoracsur.2017.08.018. Epub 2017 Nov 20. **(IF:3.7)**
12. Wang Y, Wang R, Zheng D, Han B, Zhang J, Zhao H, Luo J, Zheng J, Chen T, Huang Q, Sun Y, **Chen H***. The indication of completion lobectomy for lung adenocarcinoma ≤ 3 cm after wedge resection during surgical operation. **J Cancer Res Clin Oncol.** 2017 Oct;143(10):2095-2104. doi: 10.1007/s00432-017-2452-0. Epub 2017 Jun 14. **(IF:3.503)**
13. Cheng X, Onaitis MW, D'amico TA, **Chen H***. Minimally invasive thoracic surgery 3.0: lessons learned from the history of lung cancer surgery. **Ann Surg.** 2017 Jul 7. doi: 10.1097/SLA.0000000000002405. [Epub ahead of print] **(IF:8.569)**
14. Li B, Hu H, Zhang Y, Zhang J, Miao L, Ma L, Luo X, Zhang Y, Ye T, Li H, Zhou J, Li Y, Shen L, Zhao K, Fan M, Zhu Z, Wang J, Xu J, Deng Y, Lu Q, Jia H, Cheng X, Li H, Zhang Y, Li C, Pan Y, Liu S, Hu H, Shao L, Sun Y, Xiang J, **Chen H***. Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial. **Ann Surg.** 2017 Apr 26. doi: 10.1097/SLA.0000000000002280. [Epub ahead of print] **(IF:8.569)**
15. Zheng S, Zheng D, Dong C, Jiang J, Xie J, Sun Y, **Chen H***. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma. **J Cancer Res Clin Oncol.** 2017 Apr 13. doi: 10.1007/s00432-017-2411-9. [Epub ahead of print] **(IF:3.141)**
16. Wang Y, Wang R, Zheng D, Han B, Zhang J, Zhao H, Luo J, Zheng J, Chen T, Huang Q, Sun Y, **Chen H***. Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≤ 3 cm with wedge resection. **J Cancer Res Clin Oncol.** 2017 Feb 15. doi: 10.1007/s00432-016-2337-7. [Epub ahead of print] **(IF:3.141)**

17. Yu S, Zhang Y, Pan Y, Cheng C, Sun Y, **Chen H***. The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. **Onco Targets Ther.** 2017 Sep 12;10:4507-4515. doi: 10.2147/OTT.S131999. eCollection 2017. **(IF:2.318)**
18. Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, Hu H, Cheng C, Shen L, Wang J, Ji H, Sun Y, Zhou X, **Chen H***. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. **J Thorac Dis.** 2017 Aug;9(8):2579-2586. doi: 10.21037/jtd.2017.08.61. **(IF:2.282)**
19. Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y, Zhang Y, Yu S, Zheng D, Zhao Y, Hu H, Sun Y, Zhang Y, Xiang J, **Chen H***. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma? **J Cancer Res Clin Oncol.** 2017 Oct 12. doi: 10.1007/s00432-017-2526-z. [Epub ahead of print] **(IF:3.141)**
20. Hu H, Sun Z, Li Y, Zhang Y, Li H, Zhang Y, Pan Y, Shen L, Wang R, Sun Y*, Chen H*. The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. **J Thorac Oncol.** 2016 Aug 2. pii: S1556-0864(16)30693-1. doi: 10.1016/j.jtho.2016.07.016. [Epub ahead of print] **(IF:5.04)**
21. Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Huang Q, Wang Y, Zheng J, **Chen H***. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma. **Oncotarget.** 2016 Oct 9. doi: 10.18632/oncotarget.12540. [Epub ahead of print] **(IF:5.008)**
22. Luo J, Huang Q, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Wang Y, Zheng J, Wu H, Xia W, Chen H. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. **J Cancer Res Clin Oncol** 2016 Sep;142(9):2031-40. **(IF:3.081)**
23. Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Huang Q, Wang Y, Zheng J, **Chen H***. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. **J Cancer Res Clin Oncol** 2016 Aug;142(8):1837-45. **(IF:3.081)**

24. Yangle Huang, Rui Wang, Yunjian Pan, Yang Zhang, Hang Li, Chao Cheng, Difan Zheng, Shanbo Zheng, Yuan Li, Xuxia Shen, Haichuan Hu, Deng Cai, Shengfei Wang, Yawei Zhang, Jiaqing Xiang, Yihua Sun, Jie Zhang, **Haiquan Chen***. Clinical and genetic features of lung squamous cell cancer in never-smokers. **Oncotarget** 2016 Jun 14;7(24):35979-35988. doi: 10.18632/oncotarget.8745. **(IF:5.008)**
25. Difan Zheng, Rui Wang, Ting Ye, Su Yu, Haichuan Hu, Xuxia Shen, Yuan Li, Hongbin Ji*, Yihua Sun*, **Haiquan Chen***. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. **Oncotarget** 2016 Jul 5;7(27):41691-41702. doi: 10.18632/oncotarget.9541. **(IF:5.008)**
26. Yang Zhang, Chongze Yuan, Yawei Zhang, Yihua Sun, **Haiquan Chen***. Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer. **Oncotarget**. 2016 Apr 5;7(14):19081-6. doi: 10.18632/oncotarget.7704. **(IF:5.008)**
27. Yang Zhang, Yihua Sun, Haiquan Chen*. A propensity score matching analysis of survival following segmentectomy or wedge resection in early-stage lung invasive adenocarcinoma or squamous cell carcinoma. **Oncotarget** 2016 Mar 22;7(12):13880-5. doi: 10.18632/oncotarget.7284. **(IF:5.008)**
28. Shanbo Zheng, Rui Wang, Yang Zhang, Yunjian Pan, Chao Cheng, Difan Zheng, Yihua Sun & **Haiquan Chen***. Former Smokers with Non-Small Cell Lung Cancers: A Comprehensive Investigation of Clinicopathologic Characteristics, Oncogenic Drivers and Prognosis. **Cancer Medicine** 2016 Aug;5(8):2117-25. doi: 10.1002/cam4.764. Epub 2016 May 26. **(IF: 2.915)**
29. Gu C, Pan X, Wang R, Li Y, Shen X, Shi J, **Chen H***. Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component. **Oncotarget** 2016 Apr 26;7(17):24596-603. doi: 10.18632/oncotarget.8258. **(IF:5.008)**
30. Zhang Y, Sun Y, **Chen H***. Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. **OncoTargets and Therapy** 2016;9:649-653. **(IF:2.272)**
31. Zhao Y, Wang R, Shen X, Pan Y, Cheng C, Li Y, Shen L, Zhang Y, Li H, Zheng D, Ye T, Zheng S, Sun Y, **Chen H***. Minor components of micropapillary and solid subtypes in lung adenocarcinoma are

- predictors of lymph node metastasis and poor prognosis. **Ann Surg Oncol.** 2016 Jun;23(6):2099-105. doi: 10.1245/s10434-015-5043-9. Epub 2016 Feb 2. **(IF:3.655)**
32. Li B, Xiang J, Zhang Y, Hu H, Sun Y, **Chen H***. Factors Affecting Hospital Mortality in Patients with Esophagogastric Anastomotic Leak: A Retrospective Study. **World J Surg.** 2016 May;40(5):1152-1157. **(IF:2.523)**
33. Liu S, Wang R, Zhang Y, Li Y, Cheng C, Pan Y, Xiang J, Zhang Y, **Chen H***, Sun Y*. Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. **J Clin Oncol.** 2016 Feb 1;34(4):307-13. **(IF: 20.982)**
34. Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, Zheng S, Li H, Gong R, Li Y, Shen X, Sun Y, **Chen H***. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese population. **Onco Targets Ther.** 2016 Feb 22;9:833-43. **(IF: (IF:2.272)**
35. Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, Zheng S, Li H, Gong R, Li Y, Shen X, Sun Y, **Chen H***. Prevalence and clinic pathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. **J Cancer Res Clin Oncol.** 2016 Apr;142(4):833-43. **(IF:3.081)**
36. Xiong J, Wang R, Sun Y, **Chen H***. Lymph node metastasis according to primary tumor location in T1 and T2 stage non-small cell lung cancer patients. **Thorac Cancer.** 2016 Apr 26;7(3):304-9. **(IF:0.799)**
37. Xiong J, Wang R, Sun Y, **Chen H***. Clinical analysis of sixty-four patients with T1aN2M0 stage non-small cell lung cancer who had undergone resection. **Thorac Cancer.** 2016 Mar;7(2):215-21. **(IF:0.799)**
38. Huang Q, Li J, Sun Y, Wang R, Cheng X, **Chen H***. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small-cell lung cancer by meta-analysis. **Chest.** 2016 Jun;149(6):1384-92. doi: 10.1016/j.chest.2015.12.017. Epub 2015 Dec 24. **(IF:7.483)**
39. Li H, Hu H, Wang R, Zhang Y, Xiang J, Liu Q, Shi W, Sun Y, **Chen H***. When should 99mTc bone

- scintigraphy be performed in cT1N0 non-small cell lung cancer patients? **Medicine** (Baltimore). 2015 Dec;94(51):e2309. doi: 10.1097/MD.0000000000002309. **(IF:5.723)**
40. Li C, Gao Z, Li F, Li X, Sun Y, Wang M, Li D, Wang R, Li F, Fang R, Pan Y, Luo X, He J, Zheng L, Xia J, Qiu L, He J, Ye T, Zhang R, He M, Zhu M, Hu H, Shi T, Zhou X, Sun M, Tian S, Zhou Y, Wang Q, Chen L, Yin G, Lu J, Wu R, Guo G, Li Y, Hu X, Li L, Asan, Wang Q, Yin Y, Feng Q, Wang B, Wang H, Wang M, Yang X, Zhang X, Yang H, Jin L, Wang CY, Ji H*, **Chen H***, Wang J, Wei Q*. Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. **Sci Rep**. 2015 Oct 27;5:14237. doi: 10.1038/srep14237. **(IF:5.578)**
41. Li H, Hu H, Wang R, Li Y, Shen L, Sun Y, **Chen H***. Lung adenocarcinoma: Are skip N2 metasasis different from non-skip? **J Thorac Cardiovasc Surg**. 2015 Oct;150(4):790-5. **(IF:4.168)**
42. Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y*, **Chen H***. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. **Oncotarget**. 2015 Oct 27;6(33):34300-8 **(IF:6.359)**
43. Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang Y, Li H, Shen L, Yu Y, Sun Y*, **Chen H***. Negative Thyroid Transcription Factor 1 (TTF1) Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas. **J Thorac Oncol**. 2015 Oct;10(10):1444-50. **(IF:5.282)**
44. Cheng C, Wang R, Li Y, Pan Y, Zhang Y, Li H, Zheng D, Zheng S, Shen X, Sun Y*, **Chen H***. EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. **Sci Rep**. 2015 Sep 10;5:13959. doi: 10.1038/srep13959. **(IF:5.578)**
45. Zheng D, Wang R, Pan Y, Zheng S, Zhang Y, Li H, Cheng C, Gong R, Li Y, Shen X, Hu H, Cai D, Cheng X, Sun Y, **Chen H***. Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. **Ann Surg Oncol**. 2015 Dec;22 Suppl 3:S1284-91. **(IF:3.93)**
46. Zhang Y, Zhang Y, Chen S, Li Y, Yu Y, Sun Y*, **Chen H***. Is bronchoscopy necessary in the preoperative workup of a solitary pulmonary nodule? **J Thorac Cardiovasc Surg**. 2015 Jul;150(1):36-40. **(IF:4.168)**

47. Pan B, Wang R, Huang Y, Garfield D, Zhang J, **Chen H***. HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma. **Onco Targets Ther.** 2015 May 25;8:1185-91. **(IF:2.311)**
48. Li F, Han X, Li F, Wang R, Wang H, Gao Y, Wang X, Fang Z, Zhang W, Yao S, Tong X, Wang Y, Feng Y, Sun Y, Li Y, Wong KK, Zhai Q, **Chen H***, Ji H*. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. **Cancer Cell.** 2015 27(5):698-711. **(IF:23.523)**
49. Longsheng Miao, Yawei Zhang, Hong Hu, Longfei MA, Yihua Shun, Jiaqing Xiang, **Haiquan Chen***. Incidence and management of chylothorax after esophagectomy. **Thorac Cancer.** 2015 May;6(3):354-8. **(IF: 0.898)**
50. Jie Zhang*, Yizhou Jiang, Chunxiao Wu, Shuang Cai, Rui Wang, Ying Zhen, Sufeng Chen, Kuaile Zhao, Yangle Huang, James Luketich, **Haiquan Chen***. Comparison of clinicopathologic features and survival between eastern and western population with esophageal squamous cell carcinoma. **Journal of Thoracic Disease** 2015;7(10):1780-1786. **(IF: 1.783)**
51. Zhao Y, **Chen H***, Shi J, Fan L, Hu D, Zhao H. The correlation of morphologic features of chest computed tomographic scans with clinical characteristics of thymoma, TOC Category: Thoracic oncologic, Original Article. **Eur J Cardiothorac Surg.** 2015 Nov;48(5):698-704. **(IF: 2.814)**
52. Longsheng Miao · **Haiquan Chen*** · Jiaqing Xiang · Yawei Zhang. A High Body Mass Index in Esophageal Cancer Patients is Not Associated With Adverse Outcomes Following Esophagectomy. **J Cancer Res Clin Oncol** (2015) 141:941–950 **(IF:3.009)**
53. Li B, Xiang J, Zhang Y, Li H, Zhang J, Sun Y, Hu H, Miao L, Ma L, Luo X, Chen S, Ye T, Zhang Y, Zhang Y, **Chen H***. Comparison of Ivor-Lewis vs Sweet Esophagectomy for Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. **JAMA Surgery** 2015 Apr;150(4):292-8. **(IF:3.936)**

54. Li H, Pan Y, Wang R, Li Y, Sun Y, **Chen H***. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR–ROS1 fusion. **J Cancer Res Clin Oncol.** 2015 Jan;141(1):185-7. **(IF:3.009)**
55. Zheng S, Pan Y, Wang R, Li Y, Cheng C, Shen X, Li B, Zheng D, Sun Y*, **Chen H***. SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. **Onco Targets Ther.** 2015 Oct 19;8:3009-16. **(IF:2.311)**
56. Jie Zhang, Shenfei Wang, Lei Wang, Rui Wang, Sufeng Chen, Bing Pan, Yihua Sun, **Haiquan Chen***. Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. **OncoTargets and Therapy** 2015;8 1–9 **(IF:2.311)**
57. Xiao Ma, Ranxia Gong, Rui Wang, Yunjian Pan, Deng Cai, Bin Pan, Yuan Li, Jiaqing Xiang, Hecheng Li, Jie Zhang, Yihua Sun* and **Haiquan Chen***. Recurrent TERT promoter mutations in non-small cell lung cancers. **Lung Cancer** 2014 Oct 23;86(3):369-373. **(IF:3.737)**
58. Ye T, Pan Y, Wang R, Hu H, Zhang Y, Li H, Wang L, Sun Y, **Chen H***. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. **J Thorac Dis.** 2014 Oct; 6(10):1396-402.
59. Ye T, **Chen H***. Reply: To PMID 24055234. **Ann Thorac Surg.** 2014 Jul;98(1):390. **(IF:3.613)**
60. Deng Cai, Hang Li, Rui Wang, Yuan Li, Yunjian Pan, Haichuan Hu1, Yang Zhang, Ranxia Gong, Bin Pan, Yihua Sun, **Haiquan Chen***. Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. **OncoTargets and Therapy** 2014;7 2127–2132 **(IF:1.34)**
61. Zhang Y, Li J, Wang R, Li Y, Pan Y, Cai D, Hu H, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y*, **Chen H***. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. **Scientific Reports** 2014 Nov 24;4:7163. doi: 10.1038/srep07163. **(IF:5.078)**

62. Zhang Y, Sun Y, Wang R, Ye T, Zhang Y, **Chen H***. Meta-analysis of lobectomy, segmentectomy and wedge resection for stage I non-small cell lung cancer. **Journal of Surgical Oncology** 2015 Mar;111(3):334-40. doi: 10.1002/jso.23800. Epub 2014 Oct 16. **(IF: 2.843)**
63. Zhang Y, Wang R, Cai D, Li Y, Pan Y, Hu H, Wang L, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, **Chen H***. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. **J Thorac Oncol.** 2014 Dec;9(12):1772-8. **(IF: 5.8)**
64. Ma X, Li B, Yang S, Guo W, Zhu X, Li H*, Xiang J, Zhang Y, **Chen H***. Extent of lymph node dissection: common hepatic artery lymph node dissection can be omitted for esophageal squamous cell carcinoma. **Journal of Thoracic Disease.** 2014. Suppl 3:S325-32. **(IF: 1.783)**
65. Chen X, **Chen H***. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. **OncoTargets and Therapy** 2014;7 1689–1704. **(IF:1.34)**
66. Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, **Chen H***. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. **J Thorac Oncol.** 2014 Jun;9(6):760-8. **(IF: 5.8)**
67. Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y*, **Chen H***. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma **OncoTargets and Therapy** 2014;13;7: 1423–1437 **(IF:1.342)**
68. Zhang Y, Hu H, Wang R, Ye T, Pan Y, Wang L, Zhang Y, Li H, Li Y, Shen L, Yu Y, Sun Y, **Chen H***, Garfield D. Synchronous non-small cell lung cancers: diagnostic yield can be improved by histologic and genetic methods. **Ann Surg Oncol.** 2014 Dec;21(13):4369-74. **(IF:3.943)**
69. Rui Wang, Lei Wang, Yuan Li, Haichuan Hu, Lei Shen, Xu-Xia Shen, Yunjian Pan, Ting Ye, Yang Zhang, Xiaoyang Luo, Yiliang Zhang, Bin Pan, Bin Li, Hang Li, Jie Zhang, William Pao, Hongbin Ji, Yihua Sun, and **Haiquan Chen***. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of Non-small Cell Lung Cancer. **Clin Cancer Res.** 2014 Aug 1;20(15):4107-14. **(IF:8.193)**

70. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, **Chen H***. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. **OncoTargets and Therapy** 2014;7 567–573 **(IF:1.342)**
71. Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, Zhang Y, Ye T, Zhang Y, Li B, Shen L, Sun Y*, **Chen H***. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. **OncoTargets and Therapy** 2014;7, 513 – 524. **(IF:1.342)**
72. Lei Wang, Haichuan Hu, Yunjian Pan, Rui Wang, Yuan Li, Lei Shen, Yongfu Yu, Hang Li, Deng Cai, Yihua Sun*, **Haiquan Chen***. PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup. **Plos One** February 2014, 9(2): e88291. **(IF:3.534)**
73. Lei Wang, Rui Wang, Yunjian Pan, Yihua Sun, Jie Zhang* and **Haiquan Chen***. The Pemetrexed-containing Treatments in the Non-small Cell Lung Cancer, is -/low Thymidylate Synthase Expression Better than +/-high Thymidylate Synthase Expression? A Meta-analysis. **BMC Cancer** 2014, 14:205 doi:10.1186/1471-2407-14-205 **(IF:3.319)**
74. Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, **Chen H***. A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer. **J THORAC CARDIOV SUR** 2014 Oct;148(4):1193-9. **(IF:3.991)**
75. Zhu Z, **Chen H***, Yu W, Fu X, Xiang J, Li H, Zhang Y, Sun M, Wei Q, Zhao W, Zhao K. Number of negative lymph nodes is associated with survival in thoracic esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. **Ann Surg Oncol.** 2014 Sep;21(9):2857-63. **(IF:3.943)**
76. Yunjian Pan, Yang Zhang, Yuan Li, Haichuan Hu, Lei Wang, Hang Li, Rui Wang, Ting Ye, Xiaoyang Luo, Yiliang Zhang, Bin Li, Deng Cai, Lei Shen, Yihua Sun, **Haiquan Chen***. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. **Lung Cancer** 2014, 84(2): 121–126 **(IF:3.392)**
77. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y*,

- Chen H***. Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma. **Ann Surg Oncol**. 2014 Dec;21 Suppl 4:490-6. **(IF:3.943)**
78. Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, **Chen H***. Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma with Minor Glandular Component. **Chest**. 2014 Mar 1;145(3):473-9. **(IF:7.132)**
79. Wang Z, Sun Y, Gao B, Lu Y, Fang R, Gao Y, Xiao T, Liu XY, Pao W, Zhao Y, **Chen H***, Ji H*. Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. **Cancer Lett**. 2014 Jan 1;342(1):36-42. **(IF:4.258)**
80. Fang R, Zheng C, Sun Y, Han X, Gao B, Li C, Liu H, Wong KK, Liu XY*, **Chen H***, Ji H*. Brief Report: Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. **J Thorac Oncol**, 2014 Feb;9(2):254-8. **(IF:5.8)**
81. Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, **Chen H***, Ji H*. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. **Ann Surg Oncol**. 2013 Dec; 20 Suppl 3: 577-582 **(IF:4.12)**
82. Yiliang Zhang, Yihua Sun, Lei Wang, Ting Ye, Yuanjian Pan, Haichuan Hu, Yongfu Yu, Naiqing Zhao, Yanyan Song, David Garfield, **Haiquan Chen***. Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EG FR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. **OncoTargets and Therapy** 2013;6, 1771–1777 **(IF:2.073)**
83. Jie Zhang, Yue Yin, Xiao-Min Niu, Yun Liu, David Garfield, Su-Feng Chen, Rui Wang, Lei Wang and **Hai-Quan Chen***. CYP19A1 gene polymorphisms and risk of lung cancer. **Journal of International Medical Research** 2013, 41(3) 735–742. **(IF:0.958)**
84. Hang Li, Yunjian Pan, Yuan Li, Chenguang Li, Rui Wang, Haichuan Hu, Yang Zhang, Ting Ye, Lei Wang, Lei Shen, Yihua Sun*, **Haiquan Chen***. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. **Lung**

Cancer 2013, 79 (2013) 8-13. **(IF:3.392)**

85. Sufeng Chen, Yawei Zhang, Jie Zhang, Hong Hu, Yufan Cheng, Jianhua Zhou, Lei Shen and **Haiquan Chen*** Pulmonary benign metastasizing leiomyoma from uterine leiomyoma. **World Journal of Surgical Oncology** 2013, 11:163 **(IF:1.092)**
86. Yuan Li, Yunjian Pan, Rui Wang, Yihua Sun, Haichuan Hu, Xuxia Shen, Yongming Lu, Lei Shen, Xiongzeng Zhu*, **Haiquan Chen***. ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR. **PLoS ONE** 2013, 8(7): e69016. doi:10.1371/journal.pone.0069016 **(IF:3.73)**
87. Bin Li, **Haiquan Chen***, Jiaqing Xiang, Yawei Zhang, Yunyi Kong, David H. Garfield and Hecheng Li. Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma. **J Thorac Cardiovasc Surg** 2013;146:1198-203 **(IF:3.526)**
88. Zhang J, Garfield D, Jiang Y, Wang S, Chen S, **Chen H***. Does sex affect survival of squamous cell esophageal cancer patients? **J Clin Oncol.** 2013 Feb 20;31(6):815-6. **(IF:18.038)**
89. Zhang Y, Sun Y, Shen L, Li Y, Xiang J, Zhang Y, Hu H, **Chen H***. Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable. **Ann Surg Oncol** (2013) 20:1949–1954 **(IF:4.12)**
90. Li B, **Chen H***. Reply to the Editor. **J Thorac Cardiovasc Surg.** 2013 Mar;145(3):896-7. **(IF:3.526)**
91. Ting Ye, Yihua Sun, Yiliang Zhang, Yang Zhang, and **Haiquan Chen***. Three-Field or Two-Field Resection for Thoracic Esophageal Cancer: A Meta-analysis. **Ann Thorac Surg** 2013 Dec;96(6):1933-1941 **(IF:3.454)**
92. Rui Wang, Haichuan Hu, Yihua Sun, **Haiquan Chen*** et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. **J Clin Oncol.**2012; 30:4352-4359 **(IF:18.372)**

93. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, **Chen H***. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. **Clin Cancer Res.** 2012 18(7):1947-53. **(IF:7.742)**
94. Wang R, Pan Y, Li C, **Chen H*** et al. The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5' and 3' Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers. **Clin Cancer Res.** 2012 Sep 1;18(17):4725-32. **(IF:7.742)**
95. Liu YS, Luo XY, Li QR, Li H, Li C, Ni H, Li RX, Wang R, Hu HC, Pan YJ, **Chen HQ***, Zeng R*. Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer. **J Mol Cell Biol.** 2012 Oct;4(5):344-7. **(IF:7.667)**
96. Liu Y, Luo X, Hu H, Wang R, Sun Y, Zeng R*, **Chen H***. Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between overexpressed serum proteins and Non-small Cell Lung Cancer. **PLoS ONE** 2012;7(12): e51748. **(IF:4.092)**
97. Li B, **Chen H***, Xiang J, Zhang Y, Li C, Hu H, Zhang Y. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. **J Thorac Cardiovasc Surg.** 2012 Oct;144(4):778-86. **(IF:3.406)**
98. Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, **Chen H***. A prediction model for N2 disease in T1 non-small cell lung cancer. **J Thorac Cardiovasc Surg.** 2012;144:1360-1364 **(IF:3.406)**
99. Zhang J, Wang R, Liu S, Luketich JD, Chen S, **Chen H***, Schuchert MJ. Refinement of minimally invasive esophagectomy techniques after 15 years of experience. **J Gastrointest Surg.** 2012 Sep;16(9):1768-74. **(IF:2.826)**
100. Hu H, Ye T, Zhang Y, Zhang J, Luketich JD, **Chen H***. Modifications in retrosternal reconstruction after oesophagogastrectomy may reduce the incidence of anastomotic leakage. **Eur J Cardiothorac Surg.** 2012 Aug;42(2):359-63 **(IF:2.55)**

101. Haichuan Hu, Ting Ye, Hong Hua, **Haiquan Chen***. Reply to Thakkar et al. **Eur J Cardiothorac Surg.** 2012 Nov;42(5):906. **(IF:2.55)**
102. Fei Li, Yan Feng, Rong Fang, Zhaoyuan Fang, Jufeng Xia, Xiangkun Han, **Haiquan Chen***, Hongyan Liu*, Hongbin Ji*. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. **Cell Res.** 2012 May;22(5):928-31. **(IF:8.19)**
103. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, **Chen H***, Ji H. Lung adenocarcinomas with HER2 activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. **J Thorac Oncol** 2012 Jan;7(1):85-9. **(IF:4.04)**
104. Hu H, Yang J, Sun Y, Yang Y, Qian J, Jin L, Wang M, Bi R, Zhang R, Zhu M, Sun M, Ma H, Wei Q, Jiang G, Zhou X, **Chen H***. Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations. **Annals of Surgical Oncology** 2012; 19:2403–2410. **(IF:4.166)**
105. Hu H, Ye T, Tan D, Li H, **Chen H***. Is anterior mediastinum route a shorter choice for esophageal reconstruction? A comparative anatomic study. **Eur J Cardio-thorac Surg.** 2011(40), 1466-1469 **(IF:2.293)**
106. Luo X, Liu Y, Wang R, Hu H, Zeng R, **Chen H***. A High-quality Secretome of A549 Cells Aided the Discovery of C4b-binding Protein as a Novel Serum Biomarker for Non-small Cell Lung Cancer. **J Proteomics.** 2011 Apr 1;74(4):528-38. **(IF:5.074)**
107. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, **Chen H***. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. **J Exp Clin Cancer Res.** 2011 May 20;30:62 **(IF:1.921)**
108. Ye T, Hu H, Luo X, **Chen H***. The role of Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for qualitative diagnosis of mediastinal and hilar lymphadenopathy:A prospective analysis. **BMC Cancer.** 2011 Mar 21;11:100 **(IF:3.153)**
109. Li C, Sun Y, Fang ZY, Han XK, Fang R, Zhang Y, Pan Y, Zhang W, Ji H, **Chen H***. Comprehensive

- Analysis of Epidermal Growth Factor Receptor (EGFR) Gene Status in Lung Adenocarcinoma. **J Thorac Oncol.** 2011;6: 1016–1021 (IF:4.04)
110. Chen S, Zhou J, Zhang J, Hu H, Luo X, Zhang Y, **Chen H***. Video-assisted thoracoscopic solitary pulmonary nodule resection after CT-guided hookwire localization: 43 cases report and literature review. **Surgical Endoscopy** 2011 Jun;25(6):1723-9. (IF:3.436)
111. H. Li, S. Yang, J. Xiang, **H. Chen***. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma: does lymph node yield matter? **Dis Esophagus** 2011;24(2):108 (IF:1.536)
112. Li H, Yang S, Xiang J, **Chen H***. Establishment and characterization of primary lung cancer cell lines from Chinese population. **Acta Pharmacol Sin** 2011;32(3):385-392. (IF:1.909)
113. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, **Chen H***. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. **Lung Cancer** 2011 Nov;74(2):188-96. (IF:3.356)
114. Chen S, Zhang J, Li X, Luo X, Fang J, **Chen H***. The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. **Mol Cell Biochem.** 2011 Dec;358(1-2):257-63. (IF:2.168)
115. Li H, Yang S, Zhang Y, Xiang J, **Chen H***. Thoracic recurrent laryngeal lymph node metastases predict cervical node metastases and benefit from three-field dissection in selected patients with thoracic esophageal squamous cell carcinoma. **J Surg Oncol.** 2011 Nov 21. [Epub ahead of print]. (IF:2.428)
116. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, **Chen H***, Ji H*. Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers. **PLoS ONE.**2011;6(11):e28204. (IF:4.411)
117. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W*, **Chen H***, Ji H*. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases. **J Clin Oncol** 2010 ,28(30):4616-20 (IF:18.970)

118. Ye T, **Chen H***, Hu H, Wang J, Shen L. Malignant clear cell sugar tumor of the lung: Patient case report. **JCO.2010.29.6939. (IF:18.970)**
119. Zhang J, Chen SF, Zhen Y, Xiang J, Wu C, Bao P, Luketich J, Hu H, Zhou X, Zhang J, Yao S, **Chen HQ***. Multicenter analysis of lung cancer patients younger than 45 years in Shanghai. **Cancer**, 2010, 116(15):3656-3662. **(IF:2.88)**
120. Chen S, Zhang J, Wang R, Luo X, **Chen H***. The platinum-based treatments for advanced non-small cell lung cancer, is low negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. **Lung Cancer**, 2010,70(1):63-70. **(IF:3.356)**
121. Zhang J, **Chen H***, Luketich JD. Sentinel Lymph Node Biopsy In Esophageal Cancer: Has Its Time Come? **Ann Surg.** 2010,252(2):413-414. **(IF:7.474)**
122. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, **Chen H***, Ji H*. Spectrum of LKB1, EGFR and KRAS mutations in Chinese lung adenocarcinomas. **Journal of Thoracic Oncology**, 2010,5(8): 1130-1135. **(IF:4.04)**
123. Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, **Chen HQ***, Ji HB*. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. **Acta Pharmacol Sin.** 2010 May;31(5):647-8. **(IF:1.909)**
124. Zhang J, Niu XM, Liao ML, Liu Y, Sha HF, Zhao Y, Yu YF, Tan Q, Xiang JQ, Fang J, Lv DD, Li XB, Lu S, **Chen HQ***. Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer. **Oncol Rep.** 2010 Nov;24(5):1185-92. **(IF:1.686)**
125. Li H, Liu S, Zhu X, Yang S, Xiang J, **Chen H***. Clusterin immuno-expression and its clinical significance in patients with non-small cell lung cancer. **Lung.** 2010,188(5):423-431. **(IF:1.734)**

126. Li C, Sun Y, Pan Y, Wang Q, Yang S, **Chen H***. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis. **Lung**.2010,188(5):359-364. **(IF:1.734)**
127. Yang F, **Chen H***, Xiang J, Zhang Y, Zhou J, Hu H, Zhang J, Luo X. Relationship between tumor size and disease stage in non-small cell lung cancer. **BMC Cancer**, 2010, 10:474. **(IF:3.153)**
128. Sun Y, Fang R, Li C, Li L, Li F, Ye X, **Chen H***. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. **Biochem Biophys Res Commun**. 2010,396(2):501-507. **(IF:2.595)**
129. Zhou J, **Chen H***, Lu JJ, Xiang J, Zhang Y, Hu H, Zhou X, Luo X, Yang F, Tam J. Application of a Modified Mckeown Procedure in Esophageal Cancer. **Dis Esophagus**. 2009;22(8):687-93. **(IF:1.493)**
130. **Chen H**, Lu JJ, Zhou J, Zhou X, Luo X, Liu Q, Tam J*. Anterior Versus Posterior Routes of Reconstruction after Esophagectomy: A Comparative Anatomical Study. **Ann Thorac Surg** 2009;87:400-404. **(IF:3.644)**
131. Li H, Zhu X, Zhang Y, Xiang J, **Chen H***. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. **J Exp Clin Cancer Res**. 2009 Aug 8;28:110. **(IF:1.9)**
132. Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, **Chen HQ***. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. **Oncology report**, 2008,20: 581-587. **(IF:1.588)**
133. Zhang J, **Chen HQ***, Zhang YW, Xiang JQ. Adjuvant chemotherapy in esophageal cancer: a meta-analysis and experience from Shanghai cancer center. **J Int Med Res**,2008, 36(5):875-882. **(IF:0.938)**
134. Pan J, **Chen HQ***, Sun YH, Zhang JH, Luo XY. Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology. **Lung**

(2008) 186:255–261. (IF:1.495)

Co-author:

135. Wang S, Huang Y, Xie J, Zhuge L, Shao L, Xiang J, Zhang Y, Sun Y, Hu H, Chen S, Lerut T, Luketich JD, Zhang J*, **Chen H**. Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis. **Surg Endosc.** 2017 Sep 15. doi: 10.1007/s00464-017-5830-4. [Epub ahead of print] (IF:3.747)
136. Jiaying Deng,# Hu Chen,# Daizhan Zhou,# Junhua Zhang,# Yun Chen, Qi Liu, Dashan Ai, Hanting Zhu, Li Chu, Wenjia Ren, Xiaofei Zhang, Yi Xia, Menghong Sun, Huiwen Zhang, Jun Li, Xinxin Peng, Liang Li, Leng Han, Hui Lin, Xiujun Cai, Jiaqing Xiang, Shufeng Chen, Yihua Sun, Yawei Zhang, Jie Zhang, **Haiquan Chen**, Shijian Zhang, Yi Zhao, Yun Liu, Han Liang*, Kuaile Zhao*. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. **Nat Commun.** 2017; 8: 1533. (IF:12.124)
137. Huang H, Zhang W, Pan Y, Gao, Deng L, Li F, Li F, Ma X, Hou S, Xu J, Li P, Li X, Hu G, Li C, **Chen H**, Zhang L, Ji H*. YAP suppresses lung squamous cell carcinoma progression through deregulation of the DNp63-GPX2 axis and ROS accumulation. **Cancer Res.** 2017 Nov 1;77(21):5769-5781. doi: 10.1158/0008-5472.CAN-17-0449. Epub 2017 Sep 15. (IF:9.122)
138. Huang H, Zhang W, Pan Y, Gao Y, Deng L, Li F, Li F, Ma X, Hou S, Xu J, Li P, Li X, Hu G, Li C, **Chen H**, Zhang L, Ji H. YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation. **Cancer Res.** 2017 Nov 1;77(21):5769-5781. doi: 10.1158/0008-5472.CAN-17-0449. Epub 2017 Sep 15. (IF:9.121)
139. Wang S, Huang Y, Xie J, Zhuge L, Shao L, Xiang J, Zhang Y, Sun Y, Hu H, Chen S, Lerut T, Luketich JD, Zhang J*, **Chen H**. Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis. **Surg Endosc.** 2017 Sep 15. doi: 10.1007/s00464-017-5830-4. [Epub ahead of print] (IF:3.75)
140. Feng W, Zhang Q, Fu XL*, Cai XW, Zhu ZF, Yang HJ, Xiang JQ, Zhang YW, **Chen HQ**. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on

the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.

BMC Cancer. 2015 May 2;15(1):348. **(IF:3.319)**

141. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, Feng Y, Sun Y, Hou Y, Yang Z, Guan K, **Chen H**, Zhang L*, Ji H*. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. **Nat Commun**. 2014 Aug 13;5:4629. **(IF:10.742)**
142. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, Yao S, Sun Y, Li L, Zhang W, Ma H, Xiao Q, Ge G, Fang J, Wang H, Zhang L, Wong KK, **Chen H**, Hou Y, Ji H*. Transdifferentiation of Lung Adenocarcinoma in mice with Lkb1 Deficiency to Squamous Cell Carcinoma. **Nat Commun**, 2014;5:3261. **(IF:10.742)**
143. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, Li F, **Chen H**, Zhou Z*, Zhang L*, Ji H*. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. **Cell Res**, 2014 Mar;24(3):331-43. **(IF:11.981)**
144. Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo C, Wang X, Liu H, Deng L, Li C, Wang H, **Chen H**, Feng Y*, Ji H*. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition. **Int J Cancer**. 2014 May 15;134(10):2294-304. **(IF:5.007)**
145. Wang Q, Jia P, Li F, **Chen H**, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. **Genome Med**. 2013 Oct 11;5(10):91. **(IF:4.942)**
146. Feng Y, Wang Y, Wang Z, Fang Z, Li F, Gao Y, Liu H, Xiao T, Li F, Zhou Y, Zhai Q, Liu X, Sun Y, Bardeesy N, Wong KK, **Chen H**, Xiong ZQ, Ji H*. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. **Cancer Res**. 2012, 72(24):6502-11. **(IF:8.65)**
147. Jia P, Li F, Xia J, **Chen H**, Ji H, Pao W, Zhao Z*. Consensus rules in variant detection from next-generation sequencing data. **PLoS One**. 2012;7(6):e38470. **(IF:3.73)**

148. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, **Chen H**, Liu XY*, Ji H*. miR-143 regulates cancer glycolysis via targeting hexokinase 2. *J Biol Chem*. 2012, 287(27):23227–35. **(IF:4.651)**
149. N. Girard, C.S. Sima, D.M. Jackman, L.V. Sequist, **H. Chen**, J.C-H. Yang, H. Ji, B. Waltman, R. Rosell, M. Taron, M.F. Zakowski, M. Ladanyi, G. Riely, W. Pao. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. *EUR RESPIR J*. 2012, 39(2): 366-372. **(IF:6.355)**
150. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, **Chen H**, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. *J Clin Oncol*. 2012, 30(8):863-70. **(IF:10.038)**
151. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, **Chen H**, Ji H*. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East asian never smokers. *PLoS One*. 2011, 6(11):e28204. **(IF:4.092)**
152. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, **Chen H**, Wong KK, Ge G*, Ji H*. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. *Proc Natl Acad Sci U S A*. 2010, 107(44):18892-7. **(IF:9.771)**
153. Sun Y, Fang R, Gao B, Han X, Zhang J, Pao W, **Chen H**, Ji H*. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. *Acta Pharmacol Sin*. 2010, 31, 647-8. **(IF:1.953)**
154. Xiao N, Li H, Luo J, Wang R, **Chen H**, Chen J, Wang P*. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNF α -induced cancer cell migration. *Biochem J*. 2012 Feb 1;441(3):979-86. **(IF:4.897)**
155. Jia, PL; Li, F; Xia, JF; **Chen, HQ**; Ji, HB; Pao, W; Zhao, ZM*. Consensus Rules in Variant Detection from Next-Generation Sequencing Data. *PLoS One*. 2012; 7(6): e38470. **(IF:4.092)**